Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irofulven + Capecitabine in Thyroid Cancer
NCT00124527Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2005
- Primary completion
- Aug 2006
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of irofulven in thyroid cancer, sponsored by Eisai Co., Ltd. Primary endpoint: Objective Tumor Response Rate. Started Mar 2005; status: completed.
02
Drugs
irofulven
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT00124527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00124527.